Inventor · disambiguated record
Xiaokui Zhang
Also filed as: ZHANG XIAOKUI · ZHANG XIAOKUI K
22 granted patents·39 pending applications·124 citations·filing 1999–2023
95Inventor score
Top patents by PatentIndex Score
61 records- 0196US8263065B2Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cellsHARIRI ROBERT J·Filed 2008·Granted Sep 11, 2012·31 cites·36 claims
- 0293US8926964B2Methods of generating natural killer cellsHARIRI ROBERT J·Filed 2011·Granted Jan 6, 2015·28 cites·26 claims
- 0390US9464274B2Methods of generating natural killer cellsANTHROGENESIS CORP·Filed 2014·Granted Oct 11, 2016·13 cites·20 claims
- 0489US9216200B2Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cellsHARIRI ROBERT J·Filed 2012·Granted Dec 22, 2015·5 cites·31 claims
- 0588US11754573B2Methods for the quantitation of polypeptidesGENZYME CORP·Filed 2021·Granted Sep 12, 2023·1 cites·21 claims
- 0688US9255248B2Method of producing erythrocytes without feeder cellsANTHROGENESIS CORP·Filed 2013·Granted Feb 9, 2016·5 cites·12 claims
- 0787US8562973B2Treatment of sarcoidosis using placental stem cellsEDINGER JAMES W·Filed 2011·Granted Oct 22, 2013·12 cites·23 claims
- 0884US8586360B2Method of producing erythrocytes without feeder cellsABBOT STEWART·Filed 2010·Granted Nov 19, 2013·4 cites·14 claims
- 0982US8969315B2Enhancement of placental stem cell potency using modulatory RNA moleculesABBOT STEWART·Filed 2011·Granted Mar 3, 2015·4 cites·8 claims
- 1080US11067584B2Methods for the quantitation of polypeptidesGENZYME CORP·Filed 2019·Granted Jul 20, 2021·1 cites·21 claims
- 1177US9200253B1Method of producing erythrocytesHEIDARAN MOHAMMAD A·Filed 2008·Granted Dec 1, 2015·4 cites·11 claims
- 1276US10041043B2Method of producing erythrocytes without feeder cellsCELULARITY INC·Filed 2015·Granted Aug 7, 2018·1 cites·10 claims
- 1375US7211655B2Methods for identifying modulators of transcriptional activator protein interactionsUNIV ROCKEFELLER·Filed 2005·Granted May 1, 2007·1 cites·3 claims
- 1475US2022259563A1Methods of generating natural killer cellsCELULARITY INC·Filed 2022·Application pending·0 cites
- 1575US2023081199A1Enhanced placental stem cells and uses thereofCELULARITY INC·Filed 2022·Application pending·0 cites
- 1674US11180731B2Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cellsCELULARITY INC·Filed 2017·Granted Nov 23, 2021·1 cites·18 claims
- 1774US9763983B2Natural killer cells from placentaANTHROGENESIS CORP·Filed 2014·Granted Sep 19, 2017·2 cites·20 claims
- 1870US2023142803A1Natural killer cells and ilc3 cells and uses thereofCELULARITY INC·Filed 2022·Application pending·0 cites
- 1968US2022348875A1Genetically modified natural killer cellsCELULARITY INC·Filed 2021·Application pending·0 cites
- 2067US11512282B2Enhanced placental stem cells and uses thereofCELULARITY INC·Filed 2019·Granted Nov 29, 2022·0 cites·15 claims
- 2166US9121007B2Treatment of bone-related cancers using placental stem cellsZHANG XIAOKUI·Filed 2011·Granted Sep 1, 2015·2 cites·10 claims
- 2266US2021032596A1Method of producing erythrocytesCELULARITY INC·Filed 2020·Application pending·0 cites
- 2364US10329529B2Enhanced placental stem cells and uses thereofCELULARITY INC·Filed 2014·Granted Jun 25, 2019·0 cites·17 claims
- 2464US2021230546A1Methods for isolation of plateletsCELULARITY INC·Filed 2021·Application pending·0 cites
- 2563US2019330592A1Methods of generating natural killer cellsCELULARITY INC·Filed 2019·Application pending·0 cites
- 2663US2025295776A1Cleavage resistant cd16 constructs and uses thereofCELULARITY INC·Filed 2023·Application pending·0 cites
- 2760US2020246393A1Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibodyCELULARITY INC·Filed 2018·Application pending·0 cites
- 2859US6960647B2Stat3 protein fragments and mutantsUNIV ROCKEFELLER·Filed 2002·Granted Nov 1, 2005·2 cites·4 claims
- 2959US2021121452A1Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compoundsCELULARITY INC·Filed 2020·Application pending·0 cites
- 3057US2021008109A1Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cellsCELGENE CORP·Filed 2020·Application pending·0 cites
- 3156US2017002322A1Methods of generating natural killer cellsANTHROGENESIS CORP·Filed 2016·Application pending·0 cites
- 3256US2017240860A1Method of producing erythrocytesANTHROGENESIS CORP·Filed 2015·Application pending·0 cites
- 3355US2017000828A1Enhancement of placental stem cell potency using modulatory rna moleculesANTHROGENESIS CORP·Filed 2016·Application pending·0 cites
- 3454US8431335B2Compositions and methods for detection of lysosomal storage diseaseZHANG XIAOKUI K·Filed 2007·Granted Apr 30, 2013·2 cites·3 claims
- 3554US2019093081A1Placenta-derived intermediate natural killer (pink) cells for treatment of glioblastomaCELULARITY INC·Filed 2018·Application pending·0 cites
- 3653US2018273903A1Genetically modified natural killer cellsCELULARITY INC·Filed 2017·Application pending·0 cites
- 3752US2009104164A1Angiogenic cells from human placental perfusateCELGENE CELLULAR THERAPEUTICS·Filed 2008·Application pending·0 cites
- 3852US2022160787A1Placenta derived adherent cells for improved xenoplantationCELULARITY INC·Filed 2020·Application pending·0 cites
- 3951US6391572B1Methods for identifying modulators of transcriptional activator protein interactionsUNIV ROCKEFELLER·Filed 1999·Granted May 21, 2002·5 cites·26 claims
- 4051US2025092363A1Placenta-derived allogeneic car-t cells and uses thereofCELULARITY INC·Filed 2020·Application pending·0 cites
- 4150US2021095258A1Post partum tissue-derived induced pluripotent stem cells and uses thereofCELULARITY INC·Filed 2019·Application pending·0 cites
- 4249US2022273716A1Populations of natural killer cells comprising a cd38 chimeric antigen receptorCELULARITY INC·Filed 2020·Application pending·0 cites
- 4349US2022000919A1Placental derived natural killer cells for treatment of coronavirus infectionsCELULARITY INC·Filed 2021·Application pending·0 cites
- 4449US2023355759A1Populations of natural killer cells comprising a cleavage resistant cd16CELULARITY INC·Filed 2020·Application pending·0 cites
- 4548US10179152B2Therapy with cells from human placenta and hematopoietic cellsANTHROGENESIS CORP·Filed 2014·Granted Jan 15, 2019·0 cites·20 claims
- 4648US2016279171A1Compositions comprising human placental perfusate cells, subpopulations thereof, and their usesANTHROGENESIS CORP·Filed 2014·Application pending·0 cites
- 4748US2023210909A1Placenta-derived adherent (pda) stem cell for the treatment of adults with sars-cov-2 related acute respiratory failure and ards (covid-19)CELULARITY INC·Filed 2021·Application pending·0 cites
- 4848US2016287635A1Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cellsANTHROGENESIS CORP·Filed 2015·Application pending·0 cites
- 4947US2011280849A1Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compoundsZHANG XIAOKUI·Filed 2011·Application pending·0 cites
- 5047US2022251104A1Aromatic compounds for use in activating hematopoietic stem and progenitor cellsCELULARITY INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →